Invalid date chosen. Displaying data for the latest date instead.

Flu Stocks List


Related Industries: Aerospace & Defense Agricultural Inputs Asset Management Auto Parts Banks - Global Banks - Regional - US Biotechnology Building Materials Business Services Chemicals Confectioners Conglomerates Credit Services Diagnostics & Research Diversified Industrials Drug Manufacturers - Major Drug Manufacturers - Specialty & Generic Electronic Components Engineering & Construction Farm & Construction Equipment Grocery Stores Health Information Services Home Furnishings & Fixtures Household & Personal Products Industrial Distribution Industrial Electrical Equipment Industrial Metals & Minerals Insurance - Life Internet Content & Information Internet Content & Information Lumber & Wood Production Marketing Services Medical Care Medical Devices Medical Distribution Medical Instruments & Supplies Metal Fabrication Oil & Gas Drilling Oil & Gas Equipment & Services Oil & Gas Integrated Oil & Gas Refining & Marketing Paper & Paper Products Pollution & Treatment Controls Savings & Cooperative Banks Scientific & Technical Instruments Semiconductor Equipment & Materials Software - Application Specialty Chemicals Specialty Retail Tobacco Tools & Accessories Waste Management

Related ETFs - A few ETFs which own one or more of the above listed Flu stocks.

Flu Stocks Recent News

Date Stock Title
Jun 26 AZN AstraZeneca’s Tagrisso with chemo approved in China for lung cancer
Jun 26 AZN AstraZeneca’s Tagrisso receives approval in Japan for lung cancer
Jun 25 HON Honeywell International Inc. (HON) Stock Slides as Market Rises: Facts to Know Before You Trade
Jun 25 MRK Merck wins approval of RNA-based dog flu vaccine
Jun 25 MRK USDA Approves Merck Animal Health’s NOBIVAC® NXT Canine Flu H3N2 – The First and Only RNA-Particle Technology Vaccine for Canine Influenza
Jun 25 MRK Analyst Sees Keros Therapeutics As Next Acceleron, Set For Major Biotech Growth
Jun 25 MRK Gossamer Bio's Clean Safety Profile Differentiates It From Merck, Analyst Says
Jun 25 AZN AstraZeneca's Oncology Success: Fueling Future Growth
Jun 25 AZN AstraZeneca makes another obesity play funnelling $80m into SixPeaks Bio
Jun 25 AZN AstraZeneca lung cancer therapy Imfinzi fails in late-stage trial
Jun 25 AZN AstraZeneca's Blockbuster Cancer Drug Imfinzi Flunks As Follow-Up In Type Of Early-Stage Lung Cancer, But Hits Primary Goal In Phase 3 Bladder Cancer Study
Jun 25 MRK ASCO24: MSD’s ADC shows efficacy in lung and breast tumours
Jun 25 AZN IMFINZI® (durvalumab) demonstrated statistically significant and clinically meaningful improvement in event-free survival and overall survival for muscle-invasive bladder cancer in NIAGARA Phase III trial
Jun 25 SPLV Invesco S&P 500 Low Volatility ETF declares monthly distribution of $0.1101
Jun 25 AZN AstraZeneca’s trial of Imfinzi for lung cancer failed to meet primary endpoint
Jun 25 AZN AstraZeneca adds novel systemic lupus erythematosus target with BenevolentAI
Jun 24 MRK Merck (MRK) Increases Despite Market Slip: Here's What You Need to Know
Jun 24 PRU Retirement crisis looms as women's savings just one-third of men's: report
Jun 24 MRK Is Merck & Co., Inc. (MRK) a Strong Buy Right Now?
Jun 24 PRU 2024 Pulse of the American Retiree Survey: Midlife Retirement ‘Crisis’ or a 10-Year Opportunity?